Table 2.
Odds ratios (OR) and 95% confidence interval (CI) of MCI or dementia by baseline phospholipids (log-transformed per 1-SD change), ARIC Brain MRI Study (2004–2006) and ARIC-NCS (2011–2013)
| Phospholipid | N | MCI vs. normal, OR (95% CI)∗ | Dementia vs. normal, OR (95% CI)∗ | MCI and dementia vs. normal, OR (95% CI)∗ |
|---|---|---|---|---|
| PC aa C36:6 | ||||
| Model 0 | 221 | 1.03 (0.77–1.38) | 0.96 (0.61–1.50) | 1.01 (0.77–1.36) |
| Model 1 | 221 | 1.04 (0.77–1.40) | 0.97 (0.58–1.62) | 1.03 (0.78–1.40) |
| Model 2 | 221 | 1.10 (0.79–1.53) | 1.36 (0.49–3.77) | 1.11 (0.82–1.62) |
| PC aa C38:0 | ||||
| Model 0 | 221 | 1.04 (0.77–1.41) | 0.91 (0.62–1.35) | 1.01 (0.76–1.35) |
| Model 1 | 221 | 1.06 (0.77–1.46) | 0.86 (0.58–1.28) | 1.01 (0.75–1.37) |
| Model 2 | 221 | 1.07 (0.77–1.50) | 0.84 (0.51–1.37) | 1.02 (0.75–1.44) |
| PC aa C38:6 | ||||
| Model 0 | 221 | 1.10 (0.78–1.56) | 1.09 (0.60–1.98) | 1.10 (0.83–1.65) |
| Model 1 | 221 | 1.12 (0.79–1.59) | 1.05 (0.56–1.97) | 1.11 (0.83–1.68) |
| Model 2 | 221 | 1.16 (0.77–1.74) | 1.39 (0.38–5.12) | 1.18 (0.85–1.99) |
| PC aa C40:1 | ||||
| Model 0 | 221 | 0.98 (0.74–1.30) | 0.62 (0.33–1.18) | 0.92 (0.69–1.20) |
| Model 1 | 221 | 0.97 (0.73–1.30) | 0.63 (0.32–1.23) | 0.92 (0.69–1.21) |
| Model 2 | 221 | 1.02 (0.74–1.41) | 0.56 (0.24–1.29) | 0.95 (0.69–1.29) |
| PC aa C40:2 | ||||
| Model 0 | 221 | 1.11 (0.83–1.49) | 0.91 (0.57–1.46) | 1.07 (0.82–1.41) |
| Model 1 | 221 | 1.15 (0.85–1.55) | 0.91 (0.54–1.52) | 1.10 (0.84–1.47) |
| Model 2 | 221 | 1.20 (0.86–1.69) | 0.99 (0.50–1.97) | 1.16 (0.85–1.62) |
| PC aa C40:6 | ||||
| Model 0 | 221 | 1.07 (0.79–1.45) | 1.15 (0.62–2.15) | 1.08 (0.82–1.51) |
| Model 1 | 221 | 1.10 (0.80–1.51) | 1.11 (0.57–2.16) | 1.10 (0.83–1.57) |
| Model 2 | 221 | 1.16 (0.80–1.70) | 1.79 (0.63–5.12) | 1.20 (0.87–1.87) |
| PC ae C40:6 | ||||
| Model 0 | 221 | 1.14 (0.79–1.65) | 1.06 (0.62–1.83) | 1.12 (0.84–1.69) |
| Model 1 | 221 | 1.18 (0.79–1.77) | 1.00 (0.60–1.65) | 1.13 (0.84–1.75) |
| Model 2 | 221 | 1.20 (0.76–1.88) | 1.05 (0.45–2.42) | 1.17 (0.85–1.99) |
| Lyso PC a C18:2 | ||||
| Model 0 | 221 | 1.50 (1.01–2.23) | 1.11 (0.64–1.93) | 1.40 (1.00–2.04) |
| Model 1 | 221 | 1.49 (1.00–2.23) | 1.11 (0.60–2.06) | 1.40 (1.00–2.07) |
| Model 2 | 221 | 1.66 (1.04–2.64) | 1.17 (0.52–2.65) | 1.52 (1.03–2.37) |
| Propionyl-L-carnitine (C3) | ||||
| Model 0 | 221 | 0.97 (0.73–1.29) | 1.19 (0.73–1.96) | 1.01 (0.77–1.32) |
| Model 1 | 221 | 0.98 (0.73–1.30) | 1.24 (0.73–2.11) | 1.02 (0.77–1.34) |
| Model 2 | 221 | 0.97 (0.69–1.34) | 1.21 (0.62–2.35) | 0.98 (0.71–1.35) |
NOTE. Model 0: Unadjusted logistic regression; Model 1: Logistic regression adjusted for age, race, sex, & APOE. Model 2: Model 1 with additional adjustment for body mass index, cholesterol medications, diabetes mellitus, drinking status, educational level, HDL cholesterol, smoking status, sports index, systolic blood pressure, total cholesterol, triglycerides, use of antihypertensive medications, and prevalent coronary heart disease, heart failure, or stroke at baseline.
The Table 2 results are showing the association of phospholipid measurements at the MRI visit with incident MCI/dementia at visit 5.
Bold indicates statistical significance.
OR per 1-SD change in the log (phospholipid).